Literature DB >> 21498714

Overcoming multidrug resistance in human lung cancer with novel benzo[a]quinolizin-4-ones.

Yodsoi Kanintronkul1, Rattana Worayuthakarn, Nopporn Thasana, Pakorn Winayanuwattikun, Kovit Pattanapanyasat, Rudee Surarit, Somsak Ruchirawat, Jisnuson Svasti.   

Abstract

AIM: To investigate the ability of synthetic benzo[a]quinolizin-4-one derivatives to reverse multidrug resistance (MDR) in lung cancer cells.
MATERIALS AND METHODS: A cell line with MDR, A549RT-eto, was established by exposure to 1.5 μM etoposide. Cytotoxic activity was assayed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromine (MTT) method. The mechanism of drug resistance was studied by real-time PCR, Western blot analysis, and flow cytometry. Benzo[a]quinolizin-4-one derivatives were synthesized and tested for cytotoxic activity and ability to modulate MDR.
RESULTS: A549RT-eto cells had an IC(50) for etoposide of 176 μM, 28-fold higher than parental cells, due to increased levels of MDR1 gene and P-glycoprotein (P-gp), resulting in greater drug efflux. Three benzo[a]quinolizin-4-ones reduced etoposide IC(50) from 176 μM to 22.4 μM -24.7 μM. This resulted from increased drug accumulation without altering P-gp expression at the transcription or translation level.
CONCLUSION: Non-toxic concentrations of benzo[a]quinolizin-4-one derivatives can reverse drug resistance of A549RT-eto by increasing the intracellular drug accumulation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498714

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

Review 1.  Mechanisms of resistance to chemotherapy in non-small cell lung cancer.

Authors:  Hye-Young Min; Ho-Young Lee
Journal:  Arch Pharm Res       Date:  2021-02-19       Impact factor: 4.946

2.  Formoxanthone C Inhibits Malignant Tumor Phenotypes of Human A549 Multidrug Resistant-cancer Cells through Signal Transducer and Activator of Transcription 1-Histone Deacetylase 4 Signaling.

Authors:  Chutima Kaewpiboon; Young-Hwa Chung; Nawong Boonnak; Sirichat Kaowinn; Natpaphan Yawut
Journal:  J Cancer Prev       Date:  2022-06-30

3.  Hybrid of niosomes and bio-synthesized selenium nanoparticles as a novel approach in drug delivery for cancer treatment.

Authors:  Mahmoud Gharbavi; Behrooz Johari; Navid Mousazadeh; Bahareh Rahimi; Milad Parvinzad Leilan; Seyed Sadegh Eslami; Ali Sharafi
Journal:  Mol Biol Rep       Date:  2020-08-07       Impact factor: 2.316

4.  Studies of the in vitro cytotoxic, antioxidant, lipase inhibitory and antimicrobial activities of selected Thai medicinal plants.

Authors:  Chutima Kaewpiboon; Kriengsak Lirdprapamongkol; Chantragan Srisomsap; Pakorn Winayanuwattikun; Tikamporn Yongvanich; Preecha Puwaprisirisan; Jisnuson Svasti; Wanchai Assavalapsakul
Journal:  BMC Complement Altern Med       Date:  2012-11-13       Impact factor: 3.659

5.  Effect of three fatty acids from the leaf extract of Tiliacora triandra on P-glycoprotein function in multidrug-resistant A549RT-eto cell line.

Authors:  Chutima Kaewpiboon; Pakorn Winayanuwattikun; Tikamporn Yongvanich; Preecha Phuwapraisirisan; Wanchai Assavalapsakul
Journal:  Pharmacogn Mag       Date:  2014-08       Impact factor: 1.085

6.  Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.

Authors:  Ewelina Dratkiewicz; Aleksandra Simiczyjew; Katarzyna Pietraszek-Gremplewicz; Justyna Mazurkiewicz; Dorota Nowak
Journal:  Int J Mol Sci       Date:  2019-12-23       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.